Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent

New England Journal of Medicine

Volumn 345, Issue 15, 2001, Pages 1098-1104

  Keane, Joseph ^a   Gershon, Sharon ^b   Wise, Robert P ^b   Mirabile Levens, Elizabeth ^a   Kasznica, John ^a   Schwieterman, William D ^c   Siegel, Jeffrey N ^c   Braun, M Miles ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CROHN DISEASE; HUMAN; IMMUNE RESPONSE; INCIDENCE; LUNG BIOPSY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SWEATING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; MALE; MIDDLE AGED; RECURRENCE; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035846326     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011110     Document Type: Article

References (40)

1. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis
2. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis
3. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice
4. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology
5. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI
6. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
7. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology
8. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection
9. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients
10. New drugs for the treatment of rheumatoid arthritis
11. Infliximab approved for use in Crohn's disease: A report on the FDA GI Advisory Committee conference
12. Infliximab (Remicade) for Crohn's disease
13. Infliximab and methotrexate in the treatment of rheumatoid arthritis
14. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
15. Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems
16. Tuberculosis is not increased in rheumatoid arthritis (RA)
17. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis
18. Cell death in granulomata: The role of apoptosis
19. Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes
20. Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis
21. A tumor necrosis factor mimetic peptide activates a murine macrophage cell line to inhibit mycobacterial growth in a nitric oxide-dependent fashion
22. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages
23. New comparisons of two types of TNFα antagonists approved for rheumatoid arthritis
24. Extrapulmonary tuberculosis in the United States
25. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: Recrudescence of residuals of the primary infection or exogenous reinfection?
26. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands
27. Targeted tuberculin testing and treatment of latent tuberculosis infection
28. Invasive pulmonary aspergillosis associated with infliximab therapy
29. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population
30. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population
31. Complications of long-term steroid therapy for asthma
32. Cytokine pathways and joint inflammation in rheumatoid arthritis
33. High sensitivity of transgenic mice expressing soluble TNFK1 fusion protein to mycobacterial infections: Synergistic action of TNF and IFN-γ in the differentiation of protective granulomas
34. Thrombotic thrombocytopenic purpura and clopidogrela need for new approaches to drug safety
35. Preliminary analysis of phase I and II safety data from the Adalimumab (D2E7) Clinical Trials Program
36. Two TNF receptors
37. Tumor necrosis factor-alpha-induced lung cell expression of antiapoptotic genes TRAF1 and cIAP2
38. Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages